SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

14 May 2025 Evaluate
The company witnessed a 10.78% growth in the revenue at Rs. 16898.00 millions for the quarter ended March 2025 as compared to Rs. 15253.00 millions during the year-ago period.Net profit showed a marginal rise at Rs. 2772.70 millions for the quarter ended March 2025, as compared to corresponding quarter of last year.The company reported a good operating profit of 4560.90 millions compared to 4428.30 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 16898.00 15253.00 10.78 52857.10 43901.10 20.40 52857.10 43901.10 20.40
Other Income 395.10 531.90 -25.72 2073.50 2020.60 2.62 2073.50 2020.60 2.62
PBIDT 4560.90 4428.30 2.99 12477.90 8199.80 52.17 12477.90 8199.80 52.17
Interest 305.60 276.60 10.48 1145.60 1071.00 6.97 1145.60 1071.00 6.97
PBDT 4255.30 4151.70 2.50 11332.30 7128.80 58.97 11332.30 7128.80 58.97
Depreciation 611.70 525.00 16.51 2220.90 2052.60 8.20 2220.90 2052.60 8.20
PBT 3643.60 3626.70 0.47 9111.40 5076.20 79.49 9111.40 5076.20 79.49
TAX 870.90 895.90 -2.79 2197.40 1164.00 88.78 2197.40 1164.00 88.78
Deferred Tax 175.40 23.50 646.38 203.00 39.20 417.86 203.00 39.20 417.86
PAT 2772.70 2730.80 1.53 6914.00 3912.20 76.73 6914.00 3912.20 76.73
Equity 13243.50 13229.50 0.11 13243.50 13229.50 0.11 13243.50 13229.50 0.11
PBIDTM(%) 26.99 29.03 -7.03 23.61 18.68 26.39 23.61 18.68 26.39

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×